おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Xencor
About
Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.
- 101 - 250
Highlights
Details
- Last Funding Type
- Series E
- Last Funding Money Raised
- $15M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 1997
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 25, 2007 | Series E | $15M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Novo Nordisk
|
— | Series E |
